Alternative regimen for chemotherapy-intolerant lymphoma including practical aspects in Japan.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2025-04-06 DOI:10.1080/14737140.2025.2488317

Akihiro Ohmoto, Shigeo Fuji

{"title":"Alternative regimen for chemotherapy-intolerant lymphoma including practical aspects in Japan.","authors":"Akihiro Ohmoto, Shigeo Fuji","doi":"10.1080/14737140.2025.2488317","DOIUrl":null,"url":null,"abstract":"Introduction: With the increasing number of elderly patients with lymphoma and the emergence of novel agents, clinical investigations for patients considered intolerant to conventional cytotoxic chemotherapy are receiving more focus than before.Areas covered: This review aims to provide an overview of systemic treatment for patients with lymphoma who are intolerant to conventional chemotherapy, including practical aspects in Japan.Expert opinion: Traditional approaches include dose reduction (e.g. mini-CHOP) or non-anthracycline regimens (e.g. CVP or bendamustine-based regimens) to reduce the risk of cardiotoxicity. A recent trend is the combination of molecular-targeted agents, such as lenalidomide plus rituximab in B-cell lymphoma. However, maintaining durable responses remains a major challenge. In the future, clinical trials in elderly or frail patients are expected to investigate novel agents such as antibody-drug conjugates or bispecific T-cell engagers. In addition, comprehensive geriatric assessment for tailored therapeutic intervention or dose optimization strategies based on individual genomic data is expected in the context of prospective studies.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.9000,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2488317","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: With the increasing number of elderly patients with lymphoma and the emergence of novel agents, clinical investigations for patients considered intolerant to conventional cytotoxic chemotherapy are receiving more focus than before.

Areas covered: This review aims to provide an overview of systemic treatment for patients with lymphoma who are intolerant to conventional chemotherapy, including practical aspects in Japan.

Expert opinion: Traditional approaches include dose reduction (e.g. mini-CHOP) or non-anthracycline regimens (e.g. CVP or bendamustine-based regimens) to reduce the risk of cardiotoxicity. A recent trend is the combination of molecular-targeted agents, such as lenalidomide plus rituximab in B-cell lymphoma. However, maintaining durable responses remains a major challenge. In the future, clinical trials in elderly or frail patients are expected to investigate novel agents such as antibody-drug conjugates or bispecific T-cell engagers. In addition, comprehensive geriatric assessment for tailored therapeutic intervention or dose optimization strategies based on individual genomic data is expected in the context of prospective studies.

查看原文本刊更多论文

化疗不耐受淋巴瘤的替代方案，包括日本的实践方面。

导论：随着老年淋巴瘤患者数量的增加和新型药物的出现，对传统细胞毒性化疗不耐受患者的临床研究受到了比以往更多的关注。涵盖领域：本综述旨在概述对常规化疗不耐受的淋巴瘤患者的全身治疗，包括日本的实际情况。专家意见：传统方法包括减少剂量（如mini-CHOP）或非蒽环类药物方案（如CVP或苯达莫司汀方案），以降低心脏毒性的风险。最近的趋势是分子靶向药物的组合，如来那度胺加利妥昔单抗治疗b细胞淋巴瘤。然而，维持持久的反应仍然是一项重大挑战。在未来，老年人或体弱患者的临床试验有望研究新的药物，如抗体-药物偶联物或双特异性t细胞接合物。此外，在前瞻性研究的背景下，基于个体基因组数据的定制治疗干预或剂量优化策略的综合老年评估有望实现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.